The required automated deep-research attempt was run with Falcon and the
configured Perplexity-lite fallback. Falcon returned HTTP 402 (payment
required), and Perplexity-lite returned HTTP 401 (quota/authentication). Neither
provider produced a usable report, and no provider-named output was retained.
This review therefore uses the reviewed UniProtKB record, all ten publications
seeded from GOA, four additional primary structural/regulatory publications,
the Reactome reaction record, and a manual synthesis in
GLO1-deep-research-manual.md.
Human GLO1 (UniProtKB Q04760) is the canonical zinc-dependent glyoxalase I,
also named lactoylglutathione lyase. The 184-residue canonical protein forms a
homodimer, and its two active sites lie at the dimer interface. The enzyme
converts the glutathione-methylglyoxal hemimercaptal to
S-lactoylglutathione, the first enzymatic step of the glyoxalase pathway
PMID:7684374. Expression of the
human cDNA in E. coli confers methylglyoxal resistance and high glyoxalase I
activity, directly connecting the enzyme to detoxification
PMID:7684374.
The homodimeric structure places an essential zinc ion and substrate-binding
residues from both subunits in each active site
PMID:9218781. Mutagenesis establishes Glu172 (mature UniProt numbering Glu173)
as the catalytic proton-transfer residue: E172Q has less than 10^-5 of wild-type
activity, and the structure supports a base-catalytic role
PMID:9705294. A transition-state
analogue structure further supports a zinc-coordinated cis-enediolate
intermediate [PMID:10521255 "The structure of the complex with the enediolate analogue supports an \"inner sphere mechanism\" in which the GSH-methylglyoxal thiohemiacetal substrate is converted to product via a cis-enediolate intermediate."].
GLO1 is a predominantly cytosolic enzyme. Together with glyoxalase II, it
protects cells from reactive alpha-oxoaldehydes, especially methylglyoxal,
which arises largely from triose-phosphate breakdown
PMID:20454679. GLO1 uses the
spontaneously formed glutathione adduct; glyoxalase II then hydrolyzes
S-lactoylglutathione to D-lactate and regenerates glutathione. Consequently,
GLO1 participates directly in methylglyoxal catabolism, aldehyde detoxification,
and the glutathione-dependent glyoxalase cycle, but does not alone catalyze the
entire conversion to lactate.
Native erythrocyte GLO1 is N-terminally processed and can be modified at
Cys139 by glutathionylation. This modification strongly inhibits enzyme
activity in vitro PMID:20454679. TNF-induced phosphorylation and
NO-responsive modifications have also been reported, but the literature does
not justify turning these regulatory observations into an additional core
molecular function. The robust core remains methylglyoxal detoxification.
GLO1 overexpression suppresses etoposide- and adriamycin-induced apoptosis in
human leukemia cells, while pharmacological inhibition resensitizes a resistant
line PMID:10807791. A second
study found that GLO1 inhibition induces apoptosis preferentially in tumor lines
with high GLO1 activity PMID:11489834. These results
support the existing negative-regulation-of-apoptosis annotations in the tested
cancer/drug contexts, but they are not treated as a constitutive core function.
Mouse Glo1 data underlie the transferred osteoclast-differentiation
annotations. Both the Ensembl IEA and the curator ISS are retained as non-core
human inferences rather than promoted to a direct human function.
Cytosol/cytoplasm annotations are coherent with direct biochemical evidence
and the known pathway. Human Protein Atlas immunofluorescence also reports
nucleoplasm and plasma membrane. Those observations are retained as non-core
localizations because no reviewed primary study here demonstrates catalytic
function at either site. Urinary- and prostate-fluid exosome annotations come
from large-scale proteomics [PMID:19056867 "Overall, the analysis identified 1132 proteins unambiguously"; PMID:23533145 "In pooled EPS-urine exosome samples, ~900 proteins were detected."]. They are retained as non-core cargo observations,
not interpreted as evidence for an extracellular glyoxalase pathway.
The HuRI binary interaction with PUS10 is represented only as generic protein
binding. A single high-throughput binary interaction does not define GLO1's
molecular activity, so that annotation is marked over-annotated rather than
used in the core synthesis.
| GO annotation | Decision | Rationale |
|---|---|---|
| lactoylglutathione lyase activity (all seven records) | ACCEPT | Direct cloning, activity, mutagenesis, crystallography, and inhibitor studies establish the zinc-dependent reaction. |
| metal ion binding | MODIFY | Replace the generic InterPro term with zinc ion binding, which is demonstrated directly. |
| protein binding | MARK_AS_OVER_ANNOTATED | HuRI reports a PUS10 binary interaction, but generic binding is not an informative GLO1 activity. |
| glutathione metabolic process | ACCEPT | GLO1 acts on the glutathione-methylglyoxal hemimercaptal in the glutathione-recycling glyoxalase pathway. |
| zinc ion binding (three records) | ACCEPT | Zinc is the essential active-site metal, supported by structures, metal analysis, and mutagenesis. |
| methylglyoxal metabolic process | MODIFY | The experimentally supported direction is the more specific methylglyoxal catabolic process (GO:0051596). |
| osteoclast differentiation (two records) | KEEP_AS_NON_CORE | Orthology-based mammalian inference; no direct human experiment was found. |
| cytosol (three records) | ACCEPT | Predominant functional location of the enzyme. |
| cytoplasm | ACCEPT | Compatible broader localization; independently supported even though the cited abstract does not expose the GLO1-specific result. |
| nucleoplasm | KEEP_AS_NON_CORE | HPA immunofluorescence observation without demonstrated site-specific function. |
| plasma membrane | KEEP_AS_NON_CORE | HPA immunofluorescence observation without demonstrated site-specific function. |
| extracellular exosome (two records) | KEEP_AS_NON_CORE | Proteomic cargo observations do not establish an extracellular core function. |
| negative regulation of apoptotic process (three records) | KEEP_AS_NON_CORE | Supported in drug-treated cancer-cell contexts, not a constitutive core activity. |
| carbohydrate metabolic process | MODIFY | Too broad; replace with methylglyoxal catabolic process (GO:0051596). |